The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary ...

EMA recommended 17 drugs for marketing authorization in December, including treatments for rare heart conditions, anemia, and liver disease.

New research suggests that activation of the PPARδ protein, which is linked to inflammation, could treat or prevent diabetic cardiomyopathy, a serious heart condition.

Nat Clin Pract Urol. 2009;6(2):74-75. Clinical benefit is only one facet of clinical decision making; medical risks and financial costs also need to be considered. For example, many of the ...